Download the full report
Access the full report to learn how Singapore can enable MedTech companies to scale their innovations into enduring global businesses.
Medical technology (MedTech) demand in Asia-Pacific is expected to reach US$132 billion (S$170.9 billion) by 2030, growing at 6.9 per cent annually — a faster pace than the global market. For medtech companies looking to capture this growth, the region offers clinical, regulatory and commercial capabilities to help companies scale from innovation to global leadership.
A new report by Bain & Company, developed in partnership with EDB, SG Growth Capital, A*STAR, Enterprise Singapore and JPMorgan, identifies the key opportunities for medtech companies looking to establish or expand their presence in Asia-Pacific and offers insights on how to leverage these developments. Read to learn about:
- Closing the mid-market funding gap: With Seed and Series A rounds totalling USD $2.2 billion (S$2.85 billion) across 124 rounds in 2025, and only 10 per cent of Asia-Pacific buyout value attributed to MedTech, there is an opportunity to direct more funding toward companies as they scale from innovation to commercial maturity.
- Building regulatory and clinical talent capabilities: How companies can access professionals experienced in global regulatory pathways, international clinical trial management and quality systems needed for expansion into major markets.
- Strengthening intellectual property guardrails: How global filing strategies and stronger patent coverage can unlock licensing, partnership and acquisition opportunities as companies scale internationally.
- Developing commercialisation infrastructure: How to build the market-entry support, channel presence and key opinion leader networks needed to compete effectively beyond home markets.
- Investing in reimbursement and evidence generation: Why stronger clinical and health-economic evidence is the next frontier for companies looking to convert regulatory approval into adoption, reimbursement and revenue.
